Rahbar Yazdi, Shiva, Zare, Mohammad Hosein, Broomand, Mohammad Ali. (1402). Out-of-Field Dose Measurement by TLD Dosimetry and Estimation of Radiation-Induced Secondary Cancer Risk of Thyroid and Breast from Head Radiotherapy. سامانه مدیریت نشریات علمی, 13(5), 403-410. doi: 10.31661/jbpe.v0i0.2302-1595
Shiva Rahbar Yazdi; Mohammad Hosein Zare; Mohammad Ali Broomand. "Out-of-Field Dose Measurement by TLD Dosimetry and Estimation of Radiation-Induced Secondary Cancer Risk of Thyroid and Breast from Head Radiotherapy". سامانه مدیریت نشریات علمی, 13, 5, 1402, 403-410. doi: 10.31661/jbpe.v0i0.2302-1595
Rahbar Yazdi, Shiva, Zare, Mohammad Hosein, Broomand, Mohammad Ali. (1402). 'Out-of-Field Dose Measurement by TLD Dosimetry and Estimation of Radiation-Induced Secondary Cancer Risk of Thyroid and Breast from Head Radiotherapy', سامانه مدیریت نشریات علمی, 13(5), pp. 403-410. doi: 10.31661/jbpe.v0i0.2302-1595
Rahbar Yazdi, Shiva, Zare, Mohammad Hosein, Broomand, Mohammad Ali. Out-of-Field Dose Measurement by TLD Dosimetry and Estimation of Radiation-Induced Secondary Cancer Risk of Thyroid and Breast from Head Radiotherapy. سامانه مدیریت نشریات علمی, 1402; 13(5): 403-410. doi: 10.31661/jbpe.v0i0.2302-1595
Out-of-Field Dose Measurement by TLD Dosimetry and Estimation of Radiation-Induced Secondary Cancer Risk of Thyroid and Breast from Head Radiotherapy
1Department of Medical Physics, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
2Department of Clinical Oncology, Shahid Ramazan Zadeh Clinic, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Background: Radiation therapy, the most common form of cancer treatment, can result in late complications, such as secondary breast and thyroid cancers. Objective: This study aimed to evaluate the risk of secondary cancers using two radiobiological models of Excess Absolute Risk (EAR) and Excess Relative Risk (ERR) in patients with brain cancer undergoing radiotherapy for improved survival rates of cancer patients. Material and Methods: In this expository cross-sectional study, 45 patients under the age of 40 years underwent Whole Brain Radiotherapy (WBRT) using a compact accelerator in Shahid Ramezanzadeh Hospital, Yazd, Iran. Out-of-field organ dose measurement was performed using a Thermoluminescent Dosimeter (TLD) to determine the dose to thyroid and breast tissues. The risk of secondary cancers in these organs was calculated 3, 5, 10, 15, and 20 years after radiation therapy. Results: The mean values of thyroid cancer risk in men and women were 0.418±0.509 and 0.274±0.306, respectively. ERR values of breast cancer in 3-, 5-, 10-, 15-, and 20-year women undergoing radiation therapy were 1.084±2.938, 0.594±1.407, 0.248±0.497, 0.138±0.248, and 0.091±0.148, respectively. EAR values of breast cancer in 3-, 5-, 10-, 15-, and 20-year women following radiation therapy were 0.064±0.060, 0.077±0.071, 0.119±0.100, 0.178±0.248, and 0.259±0.178, respectively. Conclusion: After irradiation, the risk of secondary cancer is affected by factors, such as the patient’s age and gender. The secondary thyroid cancer is higher than that of other organs, such as the breast, in the patients undergoing WBRT.
Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018;36(2):85-94. doi: 10.3857/roj.2018.00290. PubMed PMID: 29983028. PubMed PMCID: PMC6074073.
Yahyapour R, Salajegheh A, Safari A, Amini P, Rezaeyan A, Amraee A, Najafi M. Radiation-induced Non-targeted Effect and Carcinogenesis; Implications in Clinical Radiotherapy. J Biomed Phys Eng. 2018;8(4):435-46. PubMed PMID: 30568933. PubMed PMCID: PMC6280111.
Shuryak I, Hahnfeldt P, Hlatky L, Sachs RK, Brenner DJ. A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation. Radiat Environ Biophys. 2009;48(3):275-86. doi: 10.1007/s00411-009-0231-2. PubMed PMID: 19499238. PubMed PMCID: PMC2714894.
Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, et al. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett. 2006;238(1):42-52. doi: 10.1016/j.canlet.2005.06.015. PubMed PMID: 16039041.
Hashibe M, Ritz B, Le AD, Li G, Sankaranarayanan R, Zhang ZF. Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett. 2005;220(2):185-95. doi: 10.1016/j.canlet.2004.10.023. PubMed PMID: 15766594.
Perry AD, Iida H, Patton LL, Wilder RS. Knowledge, Perceived Ability and Practice Behaviors Regarding Oral Health among Pediatric Hematology and Oncology Nurses. J Dent Hyg. 2015;89(4):219-28. PubMed PMID: 26304946.
Kourinou KM, Mazonakis M, Lyraraki E, Stratakis J, Damilakis J. Scattered dose to radiosensitive organs and associated risk for cancer development from head and neck radiotherapy in pediatric patients. Phys Med. 2013;29(6):650-5. doi: 10.1016/j.ejmp.2012.08.001. PubMed PMID: 22921884.
Schneider U, Agosteo S, Pedroni E, Besserer J. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys. 2002;53(1):244-51. doi: 10.1016/s0360-3016(01)02826-7. PubMed PMID: 12007965.
Council NR. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washingtine, DC: National Academics Press; 2006.
Little MP, Wakeford R. How is the risk of radiation-induced cancer influenced by background risk factors? Invited commentary on “a method for determining weights for excess relative risk and excess absolute risk when applied in the calculation of lifetime risk of cancer from radiation exposure” by Walsh and Schneider (2012). Radiat Environ Biophys. 2013;52(1):147-50. doi: 10.1007/s00411-012-0442-9. PubMed PMID: 23180111.
Abolaban F, Djouider F. Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia [Internet]. Research Square [Preprint]. 2021 [cited 2021 Jun 8]: 18 p. Available from: https://www.researchsquare.com/article/rs-574208/v1.
Zhang Y, Yan S, Cui Z, Wang Y, Li Z, Yin Y, Li B, Quan H, Zhu J. Out-of-field dose assessment for a 1.5 T MR-Linac with optically stimulated luminescence dosimeters. Med Phys. 2021;48(7):4027-37. doi: 10.1002/mp.14839. PubMed PMID: 33714229. PubMed PMCID: PMC8360091.
Hauri P. Out-of-field dose in photon radiotherapy: models and measurements [dissertation]. Z¨urich: University of Zurich; 2017.
Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol. 1978;17(6):475-84. doi: 10.3109/02841867809128178. PubMed PMID: 216238.
Daşu A, Toma-Daşu I, Olofsson J, Karlsson M. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncol. 2005;44(4):339-47. doi: 10.1080/02841860510029833. PubMed PMID: 16120542.
Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phy 2005;62(4):1195-203. doi: 10.1016/j.ijrobp.2005.03.053. PubMed PMID: 15990025.
Ahmadi M, Tavakoli MB, Amouheidari A, Alirezaei Z. Investigation of absorbed dose and estimation the risk of secondary thyroid cancer in whole brain radiotherapy. Journal of Isfahan Medical School. 2017;34(413):1590-4.
Inskip PD. Thyroid cancer after radiotherapy for childhood cancer. Med Pediatr Oncol. 2001;36(5):568-73. doi: 10.1002/mpo.1132. PubMed PMID: 11340614.
Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child. 1995;73(2):141-6. doi: 10.1136/adc.73.2.141. PubMed PMID: 7574858. PubMed PMCID: PMC1511189.
Zabihzadeh M, Shakarami Z, Birgani M, Shahbazian S, Beh‐rooz MA. Calculation of organs doses and secondary cancer risk during mantle field radiotherapy for Hodgkin’s lymphoma. Biosci Biotech Res Asia. 2015;12(spl.edn.1):71-7. doi: 10.13005/bbra/1607.